Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy

HIV Medicine

Volumn 7, Issue 7, 2006, Pages 477-483

  Fox, Julie ^a   Dustan, S ^a   McClure, M ^a   Weber, J ^a   Fidler, S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug resistant HIV; Evolution; Persistence; Transmission

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BIOASSAY; CLADISTICS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PERSISTENT VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS TRANSMISSION; WILD TYPE;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LONDON; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES;

EID: 33747728855     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00412.x     Document Type: Article

References (41)

1. Ammaranond P, Cunningham P, Oelrichs R et al. Rates of transmission of antiretroviral drug resistant strains of HIV. J Clin Virol 2003; 26: 153-161.
2. Blower SM, Aschenbach AN, Kahn JO. Predicting the transmission of drug-resistant HIV: Comparing theory with data. Lancet Infect Dis 2003; 3: 10-11.
3. Leigh Brown AJ, Frost SD, Mathews WC et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187: 683-686.
4. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002 347: 385-394.
5. Yerly S, Vora S, Rizzardi P et al. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-2292.
6. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br Med J 2001; 322: 1087-1088.
7. Dunn D. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. UK Group on Transmitted HIV Drug Resistance. Br Med J 2005; 331: 1368.
8. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001; 26: 145-150.
9. Boden D, Hurley A, Zhang L et al. HIV-1 drug resistance in newly infected individuals. J Am Med Assoc 1999; 282: 1135-1141.
10. Salomon H, Wainberg MA, Brenner B et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14: F17-F23.
11. Little SJ. Is transmitted drug resistance in HIV on the rise? It seems so. Br Med J 2001; 7294: 1074-1075.
12. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antiviral Ther 2004; 9: 695-702.
13. Routy JP, Machouf N, Edwardes MD et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS 2004; 18: 2305-2312.
14. de Mendoza C, Rodriguez C, Eiros JM et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis 2005; 41: 227-232.
15. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-F127.
16. Brenner BG, Routy JP, Petrella M et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753-1761.
17. Brenner BG, Routy JP, Petrella M et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753-1761.
18. Barbour JD, Hecht FM, Wrin T et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18: 1683-1689.
19. Pao D, Andrady U, Clarke J et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570-1573.
20. Gao X, Nelson GW, Karacki P et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344: 1668-1675.
21. Tang J, Wilson CM, Meleth S et al. REACH Study Group. Reaching for excellence in adolescent care and health. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002; 16: 2275-2284.
22. Richman DD, Bozzette S. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968-974.
23. Bhaskaran K, Pillay D, Walker SA et al. for the UK Register of HIV Seroconverters. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 2004; 18: 1471-1473.
24. De Mendoza C, Rodriguez C, Corral A. Impact of drug-resistant HIV viruses on viral load, CD4 counts and CD4 decline in recent seroconverters. XIIth International HIV Drug Resistance Workshop. Los Cabos, Mexico, June 2003 [Abstract 81].
25. Chan KC, Galli RA, Montaner JS, Harrigan PR. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003; 17: 1256-1258.
26. Markowitz M, Mohri H, Mehandru S et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet 2005; 365: 1031-1038.
27. Fidler S, Oxenius A, Brady M et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 2049-2054.
28. Johnson V, Brun-Vezinet F, Bonaventura C et al. Update of the Drug Resistance Mutations in HIV-1: 2005 recommendations of an International AIDS Society USA Panel. Topics HIV Med 2005; 13: 5157.
29. Fidler S, Frater J, Clarke J, Weber J. HIV-1 drug resistance in primary infections in the UK. Br Med J 2001; 323: 632-633.
30. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5: 140-155.
31. Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181.
32. Gerrish PJ, Garcia-Lerma JG. Mutation rate and the efficacy of antimicrobial drug treatment. Lancet Infect Dis 2003; 3: 28-32.
33. Simon V, Vanderhoeven J, Hurley A et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-1519.
34. de Ronde A, van Dooren M, van Der Hoek L et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75: 595-602.
35. Joly V, Descamps D, Peytavin G et al. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004; 48: 172-175.
36. Smith DM, Wong JK, Mai HT et al. Slow reversion of HIV transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in semen. Program and Abstracts of the XIV International HIV Drug Resistance Workshop; June 7-11, Quebec City, Quebec, Canada, Abstract 115. Antivir Ther 2005; 10: S128.
37. Garcia-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 2004; 78: 7545-7552.
38. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
39. Hecht GM, Grant RM, Petropoulos CJ et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307-311.
40. Wawer MJ, Gray RH, Sewankambo NK et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191: 1403-1409.
41. Brenner B, Routy JP, Quan Y et al. Co-Investigators of the Quebec Primary Infection Study. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18: 1653-1660. [Erratum AIDS 2004; 18: 2107].